Nicola Colclough

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 590 citations · Full text

Genetics, Pathology, Clinical Candidate +18

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 292 citations · Full text

Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure

Andrew G. Leach, Huw Jones, David A. Cosgrove et al. · Journal of Medicinal Chemistry · 2006 · 280 citations

Pharmaceutical Science, Chemical Analysis, Pharmaceutical Properties +21

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Richard A. Ward, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2013 · 257 citations · Full text

Covalent Inhibitors, Drug Target, Thiol Reactivity +19

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Nicola Colclough, Kan Chen, Peter Johnström et al. · Clinical Cancer Research · 2020 · 215 citations · Full text